{"id":403741,"date":"2020-12-21T09:05:36","date_gmt":"2020-12-21T14:05:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403741"},"modified":"2020-12-21T09:05:36","modified_gmt":"2020-12-21T14:05:36","slug":"lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/","title":{"rendered":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">TAIPEI<\/span>, <span class=\"xn-chron\">Dec. 21, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain\u00ae), an extended-release analgesic injection, from <span class=\"xn-location\">Singapore&#8217;s<\/span> Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approval from <span class=\"xn-location\">Singapore<\/span> has significance in accelerating the introduction of LT1001 in <span class=\"xn-location\">Southeast Asia<\/span>. <\/p>\n<p>According to CPHI, the annual revenue growth in the Southeast Asian pharmaceutical market is predicted to exceed 11% over the next 5 years with expected sales of <span class=\"xn-money\">$40bn<\/span> in 2020, while Cortelis reports that the pharmaceutical market in <span class=\"xn-location\">Singapore<\/span> is estimated to grow from <span class=\"xn-money\">USD 1.22 billion<\/span> in 2017 to <span class=\"xn-money\">USD 1.62 billion<\/span> by 2020, for a CAGR of 5.8%. Applications for drug approval were also submitted to the health authorities of other Southeast Asian countries, including <span class=\"xn-location\">Malaysia<\/span> and <span class=\"xn-location\">Thailand<\/span>. Applications to other ASEAN countries will soon follow.<\/p>\n<p>Lumosa CEO, Mr. Lin, stated: &#8220;We are aiming to strategically expand the regional market through approvals from pharmaceutical-advanced countries such as <span class=\"xn-location\">Singapore<\/span> and <span class=\"xn-location\">Switzerland<\/span> to facilitate the acceptance in the rest of the world. The company is looking forward to receiving additional approvals from <span class=\"xn-location\">Switzerland<\/span>, <span class=\"xn-location\">Malaysia<\/span>, and <span class=\"xn-location\">Thailand<\/span>. In the meantime, development in <span class=\"xn-location\">China<\/span> and the US are still under progress.&#8221;<\/p>\n<p>LT1001 is the world&#8217;s first week-long extended-release analgesic injection. When compared to morphine, oxycodone, and other commonly used analgesic agents for similar indications, LT1001 provides an extended analgesic effect but also has a better safety profile with low abuse potential. <span id=\"spanHghlt6be9\">These characteristics mark a unique market position for LT1001.<\/span><\/p>\n<p>\n        <b>About Lumosa<\/b>\n      <\/p>\n<p>Headquartered in <span class=\"xn-location\">Taipei, Taiwan<\/span>, Lumosa Therapeutics is a public-traded, fully integrated, mid- to late-stage specialty biotech company (6535.TWO; <a target=\"_blank\" href=\"http:\/\/www.lumosa.com.tw\/en\" rel=\"nofollow noopener noreferrer\">www.lumosa.com.tw\/en<\/a>) with an extensive pipeline focused on developing innovative products to address unmet medical needs within the stroke and neurological markets. With its expertise, the company identifies, develops, and obtains regulatory approvals of novel and proprietary pharmaceutical products. Lumosa develops transformative medicines faster in creative ways and delivers innovative therapies worldwide.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa-301196794.html\">http:\/\/www.prnewswire.com\/news-releases\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa-301196794.html<\/a><\/p>\n<p>SOURCE  Lumosa Therapeutics Co., Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=HK30529&amp;Transmission_Id=202012210902PR_NEWS_USPR_____HK30529&amp;DateId=20201221\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire TAIPEI, Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain\u00ae), an extended-release analgesic injection, from Singapore&#8217;s Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia. According to CPHI, the annual revenue growth in the Southeast Asian pharmaceutical market is predicted to exceed 11% over the next 5 years with expected sales of $40bn in 2020, while Cortelis reports that the pharmaceutical market in Singapore is estimated to grow from USD 1.22 billion in 2017 to USD 1.62 billion by 2020, for a CAGR of 5.8%. Applications for drug &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403741","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#039;s HSA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#039;s HSA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TAIPEI, Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain\u00ae), an extended-release analgesic injection, from Singapore&#8217;s Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia. According to CPHI, the annual revenue growth in the Southeast Asian pharmaceutical market is predicted to exceed 11% over the next 5 years with expected sales of $40bn in 2020, while Cortelis reports that the pharmaceutical market in Singapore is estimated to grow from USD 1.22 billion in 2017 to USD 1.62 billion by 2020, for a CAGR of 5.8%. Applications for drug &hellip; Continue reading &quot;LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T14:05:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA\",\"datePublished\":\"2020-12-21T14:05:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/\"},\"wordCount\":351,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK30529&amp;sd=2020-12-21\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/\",\"name\":\"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK30529&amp;sd=2020-12-21\",\"datePublished\":\"2020-12-21T14:05:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK30529&amp;sd=2020-12-21\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK30529&amp;sd=2020-12-21\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/","og_locale":"en_US","og_type":"article","og_title":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA - Market Newsdesk","og_description":"PR Newswire TAIPEI, Dec. 21, 2020 \/PRNewswire\/ &#8212;\u00a0Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain\u00ae), an extended-release analgesic injection, from Singapore&#8217;s Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia. According to CPHI, the annual revenue growth in the Southeast Asian pharmaceutical market is predicted to exceed 11% over the next 5 years with expected sales of $40bn in 2020, while Cortelis reports that the pharmaceutical market in Singapore is estimated to grow from USD 1.22 billion in 2017 to USD 1.62 billion by 2020, for a CAGR of 5.8%. Applications for drug &hellip; Continue reading \"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T14:05:36+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA","datePublished":"2020-12-21T14:05:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/"},"wordCount":351,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/","name":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21","datePublished":"2020-12-21T14:05:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK30529&amp;sd=2020-12-21"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore&#8217;s HSA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403741"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403741\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}